Do bloodstream infections caused by Candida auris have high mortality risk?

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-12 14:30 GMT   |   Update On 2022-09-12 14:30 GMT
Advertisement

USA: A new study published in the journal Clinical Infectious Diseases found no difference in the risk of fatality when comparing bloodstream infections (BSI) caused by Candida Auris to BSI caused by other Candida spp.

Bloodstream infections are conditions when bacteria, fungus, viruses, and parasites are found in normally sterile blood. Innumerable combinations of these bacteria are possible, leading to many different descriptions of BSIs, such as monomicrobial (containing a single microbial etiology) or polymicrobial (using a combination of microbial etiologies). Over 90% of BSIs from fungi are caused by candida. They have been placed third among late-onset sepsis etiologies in newborns and fourth among BSIs observed in the United States of America and Europe, respectively. Samuel P. Simon and colleagues undertook this study in order to examine the clinical traits and consequences of bloodstream infections brought on by Candida Auris and other Candida spp.

Advertisement

Three hospitals in Brooklyn, New York participated in this retrospective, case-control research between 2016 and 2020. Patients under the age of 18 who had received echinocandin treatment ad hoc for any Candida spp. with a positive blood culture were included in the study. 30-day mortality was the main result. 14-day clinical failure, 90-day death, 60-day microbiologic recurrence, and in-hospital mortality were considered secondary outcomes.

The key findings of this study were:

1. The final analysis comprised 196 individuals, including 83 instances of candidemia brought on by C. Auris.

2. Inverse propensity adjustment revealed that C. Auris BSI was not linked to higher chances of 30-day or 90-day death (aOR 1.014 and 0.863  respectively).

3. Patients with C. Auris had a greater risk of microbiologic recurrence within 60 days after finishing antifungal medication (aOR 4.461).

In conclusion, the outcome of this study clearly suggests that in the C. Auris group, the chance of microbiologic recurrence was greater.

Reference: 

Simon, S. P., Li, R., Silver, M., Andrade, J., Tharian, B., Fu, L., Villanueva, D., Abascal, D. G., Mayer, A., Truong, J., Figueroa, N., Ghitan, M., Chapnick, E., & Lin, Y. S. (2022). Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-control Study. In Clinical Infectious Diseases. Oxford University Press (OUP). https://doi.org/10.1093/cid/ciac735

Tags:    
Article Source : Clinical Infectious Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News